Comparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics

Show simplified metadata
dc.contributor.authorToh, Sengwee
dc.contributor.authorLi, Lingling
dc.contributor.authorHarrold, Leslie R
dc.contributor.authorBayliss, Elizabeth A.
dc.contributor.authorCurtis, Jeffrey R.
dc.contributor.authorLiu, Liyan
dc.contributor.authorChen, Lang
dc.contributor.authorGrijalva, Carlos G.
dc.contributor.authorHerrinton, Lisa J.
dc.contributor.departmentDepartment of Medicine, Division of Rheumatology
dc.contributor.departmentMeyers Primary Care Institute
dc.date2022-08-11T08:09:23.000
dc.date.accessioned2022-08-23T16:29:04Z
dc.date.available2022-08-23T16:29:04Z
dc.date.issued2012-05-01
dc.date.submitted2012-08-09
dc.description.abstractPURPOSE: Infliximab, a chimeric monoclonal anti-TNFalpha antibody, has been found to increase the risk of serious infections compared with the TNF receptor fusion protein etanercept in some studies. It is unclear whether the risk varies by patient characteristics. We conducted a study to address this question. METHODS: We identified members of Kaiser Permanente Northern California who initiated infliximab (n = 793) or etanercept (n = 2692) in 1997-2007. Using a Cox model, we estimated the propensity-score-adjusted hazard ratio (HR) and 95% confidence interval (CI) of serious infections requiring hospitalization or opportunistic infections comparing infliximab initiators to etanercept initiators. We tested whether the adjusted HR differed by age, sex, race/ethnicity, body mass index, and smoking status. RESULTS: The crude incidence rate of serious infections per 100 person-years was 5.4 (95%CI: 3.8, 7.5) in patients (95%CI: 10.4, 23.4) in patients >/= 65 years during the first 3 months following treatment initiation. Compared with etanercept, the adjusted HR during this period was elevated for infliximab in patients (HR: 3.01; 95%CI: 1.49, 6.07), but not in those >/= 65 years (HR 0.94; 95%CI: 0.41, 2.13). Findings did not suggest that the HR varied by the other patient characteristics examined. CONCLUSIONS: An increased risk of serious infections associated with infliximab relative to etanercept did not appear to be modified by patients' sex, race/ethnicity, body mass index, or smoking status. There was an indication that the increased risk might be limited to patients finding.
dc.identifier.citation<p>Pharmacoepidemiol Drug Saf. 2012 May;21(5):524-34. doi: 10.1002/pds.3238. Epub 2012 Mar 13. <a href="http://dx.doi.org/10.1002/pds.3238" target="_blank">Link to article on publisher's site</a></p>
dc.identifier.contextkey3194122
dc.identifier.doi10.1002/pds.3238
dc.identifier.issn1053-8569 (Linking)
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/meyers_pp/542
dc.identifier.pmid22411435
dc.identifier.submissionpathmeyers_pp/542
dc.identifier.urihttps://hdl.handle.net/20.500.14038/37160
dc.language.isoen_US
dc.relation<a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=22411435&dopt=Abstract">Link to Article in PubMed</a>
dc.relation.urlhttp://dx.doi.org/10.1002/pds.3238
dc.source.issue5
dc.source.journaltitlePharmacoepidemiology and drug safety
dc.source.pages524-34
dc.source.volume21
dc.subjectAntibodies, Monoclonal
dc.subjectAutoimmune Diseases
dc.subjectImmunoglobulin G
dc.subjectInfection
dc.subjectHealth Services Research
dc.subjectPrimary Care
dc.titleComparative safety of infliximab and etanercept on the risk of serious infections: does the association vary by patient characteristics
dc.typeJournal Article
dspace.entity.typePublication
html.description.abstract<p>PURPOSE: Infliximab, a chimeric monoclonal anti-TNFalpha antibody, has been found to increase the risk of serious infections compared with the TNF receptor fusion protein etanercept in some studies. It is unclear whether the risk varies by patient characteristics. We conducted a study to address this question.</p> <p>METHODS: We identified members of Kaiser Permanente Northern California who initiated infliximab (n = 793) or etanercept (n = 2692) in 1997-2007. Using a Cox model, we estimated the propensity-score-adjusted hazard ratio (HR) and 95% confidence interval (CI) of serious infections requiring hospitalization or opportunistic infections comparing infliximab initiators to etanercept initiators. We tested whether the adjusted HR differed by age, sex, race/ethnicity, body mass index, and smoking status.</p> <p>RESULTS: The crude incidence rate of serious infections per 100 person-years was 5.4 (95%CI: 3.8, 7.5) in patients (95%CI: 10.4, 23.4) in patients >/= 65 years during the first 3 months following treatment initiation. Compared with etanercept, the adjusted HR during this period was elevated for infliximab in patients (HR: 3.01; 95%CI: 1.49, 6.07), but not in those >/= 65 years (HR 0.94; 95%CI: 0.41, 2.13). Findings did not suggest that the HR varied by the other patient characteristics examined.</p> <p>CONCLUSIONS: An increased risk of serious infections associated with infliximab relative to etanercept did not appear to be modified by patients' sex, race/ethnicity, body mass index, or smoking status. There was an indication that the increased risk might be limited to patients finding.</p>
Files
Collections
UMass Chan Faculty and Researcher Publications